Responses to parliamentary questions
Question from Deputy Ken O’Flynn - PQ 39834-26
Deputy O'Flynn asked about the reimbursement of omaveloxolone (skyclarys) for individuals with Friedreich's ataxia. Read the HSE response.
From: Communications and public affairs
Published: May 2026
Updated: July 2026
Documents
Question from Deputy Ken O’Flynn - PQ 39834-26
PDF, 451KB, 3 pages
Summary
To ask the Minister for Health whether the assessment of omaveloxolone (skyclarys) included analysis of indirect societal costs associated with Friedreich's ataxia, including disability supports, caregiver burden, loss of educational participation, workforce impacts and long-term health service utilisation; and if she will provide details of the methodology used.
This is a beta version - your feedback will help us to improve it